New York Law Journal | Analysis
By Jason Rimland and Charles Goodwin | April 11, 2022
There has been an explosion of renewed interest in the psychedelic space, specifically in the medical application of psychedelic substances as a therapeutic treatment for mental and emotional disorder. This has caught the eye of some of the largest names in private equity, and investor enthusiasm is not going unnoticed.
By Amanda Bronstad | March 24, 2022
McKinsey & Co.'s arguments to dismiss opioid lawsuits have garnered amicus support from 11 states, including Connecticut and Texas, and the U.S. Chamber of Commerce and the American Tort Reform Association.
By Tom McParland | March 11, 2022
The panel upheld a lower court's dismissal of a proposed securities class action, which claimed that Bristol-Myers Squibb made material misstatements or omissions around a clinical trial to determine the drug's efficacy for treating certain kinds of lung cancers.
By Amanda Bronstad | March 11, 2022
The fees and costs outlined in the $26 billion opioid deal with Johnson & Johnson's Janssen Pharmaceuticals and three distributors are a mix of common benefit fees, contingency fees and payments to the states for outside counsel. One law professor said, "it's not like the lawyers are going to be impoverished."
New York Law Journal | Analysis
By Judi Abbott Curry | March 9, 2022
To prepare the best product liability and class action defense strategies for pharmaceuticals, medical devices and other FDA regulated products, it is often helpful to review holdings that have affected the industry and may shape the years ahead.
By Amanda Bronstad | March 8, 2022
In a pair of orders on Monday, U.S. District Judge Dan Polster, among other findings, upheld his decision to excuse three unvaccinated jurors from the trial, concluding there was "no doubt that trial would have been disrupted."
New York Law Journal | Analysis
By Michael A. Sirignano | March 3, 2022
As Michael A. Sirignano discusses in this edition of his Insurance Fraud column, opioid fraud (or allegations of such fraud) reaches into nearly every segment of the industry, from prescribing physicians and medical staff to pharmacies, and results in significant financial losses to private insurance carriers and government health insurance programs including Medicare and Medicaid.
New York Law Journal | Analysis
By Reed Brodsky and Eric J. Stock | February 28, 2022
Judge Cote's recent decision in 'FTC v. Shkreli' is a reminder that highly unusual price increases can lead to dramatically heighted antitrust risk, not only for the companies involved but also their major shareholders.
New York Law Journal | Analysis
By Barbara M. Goodstein and Joaquin M. C De Baca | February 2, 2022
In this Secured Transactions column, Barbara M. Goodstein and Joaquin M. C De Baca write that the Purdue Pharma decision calls into question an important tool in difficult reorganizations, a tool which is frequently used to garner, and sometimes force, consensus among disputing parties.
New York Law Journal | Analysis
By Rob Maier | February 2, 2022
'Biogen Int'l GMBH v. Mylan Pharms.' highlights the importance of considering invalidity under the written description requirement as a potential defense in litigation—particularly in ANDA cases, in which therapeutic efficacy for specific conditions, and drugs dosage amounts, may be at issue—and for patent applicants to remain mindful of written description pitfalls throughout patent prosecution.
Presented by BigVoodoo
The New York Law Journal honors attorneys and judges who have made a remarkable difference in the legal profession in New York.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Epstein Becker & Green is seeking an associate to joins its Commercial Litigation practice in our Columbus or Cincinnati offices. Ca...
McCarter & English, LLP, a well established and growing law firm, is actively seeking a talented and driven associate having 2-5 years o...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS